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Hotspot mutations in IDH1 and IDH2 cause a differentiation block that can promote tumorigenesis. Two
recent papers reported that small molecules targetingmutant IDH1 ormutant IDH2 release this differentiation
block and/or impede tumor growth, providing a proof-of-concept that mutant IDHs are therapeutically
targetable and that their effects are reversible.The isocitrate dehydrogenases IDH1 and
IDH2 are mutated in a variety of cancers,
including progressive gliomas and acute
myelogenous leukemia (AML). These
mutations cause IDH1 or IDH2 to produce
R-2-hydroxyglutarate (2HG), an oncome-
tabolite responsible for global changes
to DNA methylation, inhibition of histone
lysine demethylases, blocks to cellular
differentiation, and ultimately, tumorigen-
esis (Figueroa et al., 2010; Lu et al., 2012;
Sasaki et al., 2012; Turcan et al., 2012).
The presence of IDH mutations in a
wide variety of cancers together with
the hotspot nature of these mutations
makes them attractive therapeutic target
candidates. Recently, two studies pub-
lished in Science characterized the
use of small molecules that specifically
target mutant IDH1 or mutant IDH2 (Rohle
et al., 2013; Wang et al., 2013).The inhib-
itors restored 2HG levels to normal
physiological levels and reversed several
of the biological and epigenetic pheno-
types exerted by IDH mutations. These
proof-of-concept studies, showing that
IDH mutations are targetable by small
molecules, highlight a promising thera-
peutic avenue that necessitates further
investigation.
The understanding of the complexities
underlying IDH mutations have evolved
since their discovery in progressive gli-
omas (Yan et al., 2009). Pioneering
studies in AML and progressive gliomas
show that IDH mutations induce a pro-
moter-associated CpG-island methylator
phenotype with direct effects on gene
expression (Figueroa et al., 2010; Noush-
mehr et al., 2010). The gene expression
profile of mutant cells confers a block
to the normal differentiation program,570 Cancer Cell 23, May 13, 2013 ª2013 Elsleading to an expansion of progenitor
cells that is thought to be a critical step
in cancer pathogenesis (Duncan et al.,
2012; Turcan et al., 2012). These obser-
vations raised the possibility that inhibit-
ing IDH mutants might reverse their
tumorigenic effects (Jin et al., 2012) and
that the design of effective inhibitors
would need to take into account the
complex downstream effects of IDH
mutations.
To assess this therapeutic possibility in
the glioma context, Rohle et al. (2013)
used AGI-5198, a small molecule inhibitor
of the most common IDH mutation in
gliomas, IDH1-R132H. Treatment of an
oligodendroglioma cell line harboring an
endogenous IDH1-R132H mutation with
this inhibitor reduced growth in soft
agar by 40%–60% and impeded the
growth of xenograft tumors derived
from that cell line in mice. Analysis of
these tumors showed a reduction in
proliferative markers but no change in
apoptosis, suggesting that the altered
tumor growth was due to failure to prolif-
erate as opposed to cell death. Following
treatment, several genes involved in
glial differentiation were upregulated and
found to have lost repressive histone
marks H3K9me3 and H3K27me3 at
their promoters, implying that the mutant
IDH1 inhibitor is capable of erasing his-
tone modifications that influence gene
expression. This study demonstrated
that, in this model, targeting mutant
IDH1 can impair glioma growth in vivo,
and this growth inhibition is linked to
changes in differentiation.
Concurrently, Wang et al. (2013) de-
signed AGI-6780, a small molecule that
inhibits the most commonly occurringevier Inc.IDH mutation in AML, IDH2-R140Q, by
holding the protein in an open confor-
mation (Figure 1). They then used this in-
hibitor to explore the effects of inhibiting
mutant IDH in cells of the hematopoietic
system. Treatment with this inhibitor
lowered 2HG to normal physiological
levels in an erythroleukemia cell line
ectopically expressing IDH2-R140Q. The
inhibitor also released these cells from
the block to differentiation following
induction with erythropoietin that was
exerted by IDH2-R140Q expression.
Complementary studies treating IDH2-
mutated primary human AML cells
showed a similar reduction in 2HG levels.
However, in the mutant primary cells, a
burst of proliferation resulted followed
by an increase in mature cell types at
the expense of progenitor cells. These
results imply that mutant IDH2 inhibition
can be used to promote differentiation
of mutated AML cells. This was similar to
the Rohle et al. (2013) finding, where
genes involved in differentiation were
expressed following treatment with the
inhibitor, suggesting that mutant IDH
imparts a block to differentiation that is
released upon treatment with inhibitor.
The mutant IDH2 inhibitor’s ability to
reduce 2HG to baseline levels, coupled
with its differentiating effects on the AML
cells, opens up avenues to treat AML
and to determine the efficacy of this small
molecule inhibitor alone or in combination
with other therapeutics. The well-charac-
terized nature of the hematopoietic
system will permit many eloquent and
exciting studies analyzing AGI-6780’s
effectiveness in an in vivo animal context.
Several hurdles must be overcome
before the strategy of targeting IDH
Figure 1. Small Molecule Inhibitor AGI-6780 Binds to Mutant IDH2 and Releases a Block to Differentiation
IDHmutations induce a block to normal differentiation programs, leading to accumulation of progenitor cells, as depicted by aWaddington epigenetic landscape
on the left. AGI-6780, shown in green, binds allosterically at the mutant IDH2 homodimer interface and holds the enzyme in the catalytically inactive open con-
formation (middle). Each member of the IDH2 homodimer pair is shown in purple and teal, respectively, with the R140Q mutation in yellow. Inhibition of mutant
IDH2 releases the block and induces differentiation (right).
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Previewsmutations can be translated to the clinic.
These inhibitors were tested on a select
few cell lines, and, in the case of the
mutant IDH1 inhibitor, only on one glioma
cell line. Whether that inhibitor will work
similarly in an astrocytic glioma line as it
did in an oligodendroglial line or in a gli-
oma line of a lower or higher tumor grade,
will need to be established. Examination
of long-term mutant IDH inhibition will be
necessary to determine whether growth
inhibition can be maintained over time or
can be used together with conventional
therapeutics. Additionally, all glioma xe-
nografts in the mutant IDH1 inhibitor
studies were heterotopic. Though it is
promising that the inhibitor was capable
of reducing intratumoral 2HG levels in
these subcutaneous tumors, its ability to
cross the blood-brain-barrier and inhibit
glioma growth in the brain is imperative
for its success. Though genetically engi-
neered mouse models that express
mutant IDH1 in the brain would be an ideal
system to assess the efficacy of the IDH1
inhibitor, such models have been unsuc-
cessful in generating tumors. However,
orthotopic xenograft models would be a
viable option to address this issue. In
addition, although the mutant IDH1
inhibitor inhibited glioma cell growth, itsinability to induce apoptosis is concerning
from a therapeutic standpoint. Deter-
mining the long-term fate of those cells
exhibiting growth inhibition will be criti-
cally important. In the case of the mutant
IDH2 inhibitor, these in vitro findings
must be verified in animal models of
IDH2-mutated AML.
Nevertheless, the proof-of-concept
experiments presented by Rohle et al.
(2013) and Wang et al. (2013) contribute
greatly to the field by showing the poten-
tial for targeting IDH mutations through
small molecule inhibitors. Especially
encouraging is the fact that cells without
IDH mutations were tolerant to treatment
with the inhibitors. Intriguingly, promotion
of cellular differentiation was a major
component of the therapeutic response
in all of the above experiments; the
in vitro and in vivo ablation of excessive
2HG allows the IDH mutant-mediated
differentiation block to be lifted, permit-
ting expression of normal differentiation
programs. Given the prevalence of IDH
mutations in a variety of cancers, the
demonstration that efficient and selective
targeting of these mutations can be
achieved and can act as a therapeutic
strategy holds great promise for a large
number of patients. Though furtherCancer Celanalysis is required to generalize the
efficacy of these inhibitors in reversing
the differentiation block and oncogenic
effects imparted by 2HG, the contribution
of these tools to understanding the
biology of IDH mutations is invaluable.REFERENCES
Duncan, C.G., Barwick, B.G., Jin, G., Rago, C.,
Kapoor-Vazirani, P., Powell, D.R., Chi, J.T., Bigner,
D.D., Vertino, P.M., and Yan, H. (2012). Genome
Res. 22, 2339–2355.
Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward,
P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasan-
thakumar, A., Fernandez, H.F., et al. (2010). Cancer
Cell 18, 553–567.
Jin, G., Pirozzi, C.J., Chen, L.H., Lopez, G.Y., Dun-
can, C.G., Feng, J., Spasojevic, I., Bigner, D.D., He,
Y., and Yan, H. (2012). Oncotarget 3, 774–782.
Lu, C.,Ward, P.S., Kapoor, G.S., Rohle, D., Turcan,
S., Abdel-Wahab, O., Edwards, C.R., Khanin, R.,
Figueroa, M.E., Melnick, A., et al. (2012). Nature
483, 474–478.
Noushmehr, H., Weisenberger, D.J., Diefes, K.,
Phillips, H.S., Pujara, K., Berman, B.P., Pan, F.,
Pelloski, C.E., Sulman, E.P., Bhat, K.P., et al.
(2010). Cancer Cell 17, 510–522.
Rohle, D., Popovici-Muller, J., Palaskas, N.,
Turcan, S., Grommes, C., Campos, C., Tsoi, J.,
Clark, O., Oldrini, B., Komisopoulou, E., et al.
(2013). Science. Published online April 4, 2013.
http://dx.doi.org/10.1126/science.1236062.l 23, May 13, 2013 ª2013 Elsevier Inc. 571
Cancer Cell
PreviewsSasaki, M., Knobbe, C.B., Munger, J.C., Lind, E.F.,
Brenner, D., Brustle, A., Harris, I.S., Holmes, R.,
Wakeham, A., Haight, J., et al. (2012). Nature
488, 656–659.
Turcan, S., Rohle, D., Goenka, A., Walsh, L.A.,
Fang, F., Yilmaz, E., Campos, C., Fabius, A.W.,572 Cancer Cell 23, May 13, 2013 ª2013 ElsLu, C., Ward, P.S., et al. (2012). Nature 483,
479–483.Wang, F., Travins, J., Delabarre, B., Penard-Lacro-
nique, V., Schalm, S., Hansen, E., Straley, K., Ker-
nytsky, A., Liu, W., Gliser, C., et al. (2013). Science.evier Inc.Published online April 4, 2013. http://dx.doi.org/
10.1126/science.1234769.
Yan, H., Parsons, D.W., Jin, G., McLendon, R.,
Rasheed, B.A., Yuan, W., Kos, I., Batinic-Haberle,
I., Jones, S., Riggins, G.J., et al. (2009). N. Engl.
J. Med. 360, 765–773.
